On September 22, 2020 ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, reported on 2 September 2020 that following the placing, both Lind Global Macro Fund, LP ("Lind") and L1 Capital Global Master Opportunities Fund ("L1") had the right to require repayment of a portion of their convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020 (Press release, ImmuPharma, SEP 22, 2020, https://www.immupharma.co.uk/repayment-convertible-security-lind-global-macro-fund-lp/ [SID1234565481]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company announces that Lind has requested repayment of part of its convertible security. The amount to be repaid in accordance with the terms of the convertible security deed is $1,068,762.50 leaving an amount outstanding under the Lind convertible security of $355,112.50.

L1 has not exercised its right to repayment.

Following the repayment the Company still expects to have sufficient cash resources to fund operations through the end of 2023.